<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacokinetics for IV opioids used in the perioperative setting</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacokinetics for IV opioids used in the perioperative setting</h1>
<div class="graphic"><div class="figure"><div class="ttl">Pharmacokinetics for IV opioids used in the perioperative setting</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="10%"></colgroup> <colgroup span="5" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Drug class</td> <td class="subtitle1">Speed of onset (minutes)</td> <td class="subtitle1">Context-sensitive half time*</td> <td class="subtitle1">Duration of action and elimination half-life</td> <td class="subtitle1">Metabolism and clearance</td> <td class="subtitle1">Drug-drug interactions</td> <td class="subtitle1">Comments</td> </tr> <tr> <td>Fentanyl</td> <td>Phenylpiperidine opioid</td> <td>4 to 6 minutes</td> <td>May be prolonged and continues to increase as duration of infusion increases (for example, after infusion for 200 minutes, approximately 200 more minutes are necessary to achieve a 50% decrease in effect site concentration).</td> <td> <p>Duration of action (after a bolus dose): 30 to 45 minutes.</p> Elimination half-life: 3 to 6 hours. </td> <td> <p>Metabolized in liver by cytochrome CYP3A4 to norfentanyl (an inactive metabolite).</p> Metabolite excreted by kidney with clearance 8 mL/kg per minute. </td> <td> <p>Synergistic effects if coadministered with other anesthetic agents.</p> <p>Caution with coadministered serotonergic agents due to increased risk of serotonin syndrome.</p> Caution with CYP3A4 inhibitors (eg, diltiazem, ritonavir, voriconazole), which may increase plasma levels of fentanyl.<sup>¶</sup> </td> <td> <p>Longest duration of action in the phenylpiperidine family.</p> Pharmacokinetics unaffected by renal or hepatic insufficiency. </td> </tr> <tr> <td>Remifentanil</td> <td>Phenylpiperidine opioid</td> <td>1 to 2 minutes</td> <td> <p>Approximately 5 minutes.</p> Duration of action is not affected by duration of infusion. </td> <td> <p>Duration of action: 3 to 10 minutes.</p> Elimination half-life: 10 to 20 minutes. </td> <td> <p>Metabolized by nonspecific esterases in plasma, red blood cells, and interstitial tissue to remifentanil acid (an inactive metabolite).</p> Metabolite excreted by kidney with clearance of 40 mL/kg per minute. In older adults, clearance reduced by ~25%. </td> <td>Synergistic effects if coadministered with other anesthetic agents.</td> <td> <p>Fastest onset and shortest duration of action compared with other opioids.</p> <p>Higher incidence of hypotension compared with other opioids.</p> <p>Need for alternative analgesic agent or technique during emergence and the postoperative period if pain is anticipated.</p> In selected circumstances, may be used for a remifentanil intubation technique. </td> </tr> <tr> <td>Sufentanil</td> <td>Phenylpiperidine opioid</td> <td>3 to 5 minutes</td> <td>Context-sensitive half time plateaus at 30 to 45 minutes (shorter than fentanyl).</td> <td> <p>Elimination half-life: 2 to 4 hours.</p> Prolonged half-life reported in patients undergoing certain procedures.<sup>Δ</sup> </td> <td> <p>Metabolized in liver and small intestines by cytochrome CYP3A4 to inactive metabolites.</p> Metabolites excreted by kidney with renal clearance 12 mL/kg per minute. </td> <td> <p>Synergistic effects if coadministered with other anesthetic agents.</p> Similar to fentanyl, use caution with CYP3A4 inhibitors (eg, diltiazem, ritonavir, voriconazole), which may increase plasma levels of sufentanil<sup>¶</sup>. </td> <td> <p>Used for longer procedures when continuous opioid administration and a postoperative analgesic effect are desirable, and rapid emergence is not needed.</p> Likelihood of muscle and chest wall rigidity, particularly if administered rapidly or in high doses. </td> </tr> <tr> <td>Alfentanil</td> <td>Phenylpiperidine opioid</td> <td>1 to 3 minutes</td> <td>Context-sensitive half time plateaus at 30 to 45 minutes (shorter than fentanyl).</td> <td>Elimination half-life: 1.5 to 2 hours.</td> <td> <p>Metabolized in liver by cytochrome CYP3A4 to noralfentanil (an inactive metabolite).</p> Excreted by kidney with renal clearance 5 mL/kg per minute. </td> <td> <p>Synergistic effects if coadministered with other anesthetic agents.</p> Similar to fentanyl, use caution with CYP3A4 inhibitors (eg, diltiazem, ritonavir, voriconazole), which may increase plasma levels of alfentanil. </td> <td> <p>Avoided in patients with risk factors for seizures due to focal activation of the cerebral cortex in susceptible patients.</p> Hepatic metabolism less predictable compared with fentanyl due to inter-individual variability in activity of hepatic CYP3A4. </td> </tr> <tr> <td>Hydromorphone</td> <td>Semi-synthetic phenanthrene opioid</td> <td>Within 10 minutes</td> <td>N/A</td> <td> <p>Duration of action: 2 to 4 hours.</p> Elimination half-life: 2 to 3 hours. </td> <td> <p>Metabolized in liver to glucuronide metabolites.</p> Hydromorphone-3-glucoronide excreted by kidney; may accumulate with renal insufficiency. </td> <td>Synergistic effects if coadministered with other anesthetic agents.</td> <td> <p>Suitable for treatment of postoperative pain.</p> Caution with use in patients with renal insufficiency due to likely accumulation of hydromorphone-3-glucoronide, which causes neuroexcitation that may result in myoclonus or exacerbation of seizures; reduce dose and increase dosing interval. </td> </tr> <tr> <td>Morphine</td> <td>Phenanthrene opioid</td> <td>Within 20 minutes</td> <td>N/A</td> <td> <p>Duration of action: 4 to 6 hours (but up to 7 hours for active morphine-6-glucuronide metabolite).</p> Elimination half-life: 2 to 3 hours, but 7 hours for active metabolite. </td> <td> <p>Metabolized in liver to glucuronide metabolites (morphine-6-glucoronide and morphine 3-glucoronide).</p> Morphine-6-glucoronide is an active metabolite and is excreted by kidney with renal clearance 2.2 mL/kg per minute; may accumulate with renal insufficiency. </td> <td>Synergistic effects if coadministered with other anesthetic agents.</td> <td> <p>Suitable for treatment of postoperative pain.</p> <p>Unsuitable for use in patients with renal insufficiency (CrCl &lt;30 mL/minute) due to likely accumulation of morphine-6-glucoronide, which produces ongoing analgesia, and possible neuroexcitation that may result in myoclonus or exacerbation of seizures.</p> Histamine release and vagally mediated venodilation, hypotension, and bradycardia may be intolerable in some patients. </td> </tr> <tr> <td>Methadone</td> <td>Diphenylheptane synthetic opioid</td> <td>6 to 8 minutes</td> <td>N/A</td> <td> <p>Redistribution half-life: approximately 6 minutes.</p> <p>Elimination half-life: approximately 30 hours (range 8 to ≥59 hours).</p> Duration of action is highly dependent on dose and frequency. </td> <td>Metabolized in the liver by cytochrome P450 enzymes, primarily CYP3A4 and 2B6 but also CYP2D6 and other CYP enzymes. No active metabolites. Excretion is primarily fecal.</td> <td> <p>Extensive drug-drug interactions.</p> <p>CYP3A4 inducers may result in rapid metabolism leading to withdrawal, while inhibitors may result in prolonged effects.</p> <p>Antiretroviral agents including ritonavir-boosted regimens in particular are metabolized via similar mechanisms and have alternating induction, inhibition, or mixed effects on P450 enzymes; refer to UpToDate topic discussion. Caution with coadministered serotonergic agents due to increased risk of serotonin syndrome.</p> Review of interactions with specific agents should be considered before initiation of methadone therapy, especially on a chronic basis<sup>¶</sup>. </td> <td> <p>Unique among opioids as it has NMDA antagonist effects as well as serotonin and norepinephrine reuptake inhibition. These effects also contribute to the analgesic efficacy of methadone.</p> <p>May prolong QT interval.</p> Significant risk of accumulation with repeated doses and when titrating. </td> </tr> <tr> <td>Meperidine</td> <td>Synthetic opioid</td> <td>&lt;10 minutes</td> <td>3 hours<sup>[1]</sup></td> <td>Approximately 3 to 4 hours. Extended in the setting of hepatic dysfunction. Normeperidine metabolite has half-life up to 48 hours; thus, accumulation can occur with repeat dosing.</td> <td> <p>Metabolized in the liver by cytochrome P450, primarily CYP3A4.</p> <p>Normeperidine is the most clinically relevant metabolite, with less analgesic effect but more CNS excitability.</p> Excretion of metabolites is dependent on kidney function. </td> <td> <p>Co-administration with serotonergic agents increases risk of serotonin syndrome.</p> <p>Co-administration with MAOI is contraindicated due to potentially fatal reaction.</p> Interacts with drugs that alter CYP3A4 metabolism<sup>¶</sup>. </td> <td> <p>Limited utility for analgesia due to adverse effect profile.</p> Most common use is for postoperative shivering. </td> </tr> <tr> <td>Nalbuphine</td> <td>Phenanthrene synthetic opioid</td> <td>2 to 3 minutes (IV route), &lt;15 minutes (subcutaneous or intramuscular)</td> <td>Unknown</td> <td>3 to 6 hour duration, and 5 hour half-life.</td> <td> <p>Hepatic metabolism by UGT2B7 to largely inactive metabolites.<sup>[2,3]</sup></p> Fecal/biliary excretion of both active drug and metabolites (80 to 90% within 7 hours of administration). </td> <td>Administration to patients taking mu-opioid agonists can precipitate opioid withdrawal.</td> <td> <p>Primary usage is at sub-anesthetic doses (2.5 to 5 mg IV) to reverse opioid-related adverse effects without reversal of analgesia.</p> In opioid-naïve patients, doses of 10 mg IV can provide analgesia. </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>IV: intravenous; CYP: cytochrome; N/A: not applicable; CrCl: creatinine clearance; NMDA: N-methyl-D-aspartate; MAOI: monoamine oxidase inhibitor.</p>
<p>* Context-sensitive half time is the time in minutes required for a 50% decrease in effect site concentration after the infusion is discontinued.</p>
<p>¶ Lists of drugs that alter CYP3A4 and CYP2D6 metabolism are available as separate tables within UpToDate. Significant drug interactions may be identified by use of the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> program available through UpToDate.</p>
Δ As examples, a longer half-life of sufentanil has been reported in patients undergoing cardiac surgery (9.9 hours) and abdominal aortic surgery (12 hours)<sup>[4,5]</sup>.</div><div class="graphic_reference">References:
<ol>
<li>Whitener S, McEvoy MD, Shafer SL, Flood P. The Pharmacology of Intravenous Opioids. In: Geriatric Anesthesiology, Reves J, Barnett S, McSwain J, Rooke G (Eds), Springer 2017. p. 283.</li>
<li>Arnould JF, Pinaud M. Pharmacology of nalbuphine. Ann Fr Anesth Reanim 1992; 11:221.</li>
<li>Wang H-J, Hsiong C-H, Ho S-T, et al. Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans. Pharm Res 2014; 31:1676.</li>
<li>Howie MB, Smith DF, Reilley TE, et al. Postoperative course after sufentanil or fentanyl anesthesia for coronary artery surgery. J Cardiothorac Vasc Anesth 1991; 5:485.</li>
<li>Hudson RJ, Bergstrom RG, Thomson IR, et al. Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery. Anesthesiology 1989; 70:426.</li>
</ol></div><div id="graphicVersion">Graphic 111780 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
